Gland Pharma Limited (“Gland Pharma” or the “Company”) has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest-growing injectable focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
Gland Pharma operates primarily under a business-to-business (B2B) model and has an excellent track record in the development, manufacturing, and marketing of sterile injectables.
The Company has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, and also enjoys the distinction of having pioneered Heparin technology in India.
USA, Europe, Canada and Australia (Core Markets) – Continuing on its strategy to strengthen product portfolio, the Company launched key products like Micafungin, Bivalirudin and Ziprasidone in core markets which has helped maintain strong growth.
New launches:
Q4 FY21: 16 Product SKUs (10 molecules) FY21: 47 Product SKUs (28 molecules).
Domestic Market – Domestic market sales remain steady and have shown 19% growth in FY21. The Company ramped up Remdesivir supply for the domestic market considering the requirement for Indian patients.
New launches: FY21: 10 Product SKUs (6 molecules)
Extensive Portfolio of Complex Products – Present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings.
Delivery Systems: • Liquid vials • Lyophilized vials • pre-filled syringes • Ampoules • Bags • Drops
Therapeutic Areas: Anti-diabetic • Anti-infectives • Anti-malarials • Anti-neoplastics (Oncology) • Blood-related • Cardiac • Gastro-intestinal • Hormones • Neurological and Central Nervous System • Ophthalmics and Otologicals • Pain, neuro-muscular blocking agents & analgesics • Respiratory • Vitamins, minerals & nutrients
Financial Details
| Particulars | FY17 | FY18 | FY19 | FY20 | FY21 |
| Revenue (In Rs. Cr.) | 1,479.18 | 1,619.94 | 2,044.20 | 2,633.24 | 3,462.88 |
| Growth | – | 9.52% | 26.19% | 28.82% | 31.51% |
| EBITDA (In Rs. Cr.) | 624.99 | 535.11 | 706.31 | 955.47 | 1,302.23 |
| EBITDA Margin | 42.25% | 33.03% | 34.55% | 36.28% | 37.61% |
| EBIT (In Rs. Cr.) | 550.84 | 456.90 | 624.35 | 860.88 | 1,203.45 |
| EBIT Margin | 37.24% | 28.20% | 30.54% | 32.69% | 34.75% |
| PBT (In Rs. Cr.) | 578.01 | 501.56 | 686.36 | 992.87 | 1,334.81 |
| PAT (In Rs. Cr.) | 413.73 | 321.11 | 451.91 | 772.86 | 996.96 |
| PAT Margin | 27.97% | 19.82% | 22.11% | 29.35% | 28.79% |
| EPS (In Rs.) | 25.24 | 19.59 | 27.57 | 47.15 | 60.83 |
| EPS Growth Rate | – | -22.39% | 40.73% | 71.02% | 29.00% |
| Historic P/E (Closing Price of 31st March) | – | – | – | – | 40.74 |
| CURRENT P/E | 59.69 | ||||
| CURRENT PE/ROE | 3.53 | ||||
| PE/ROE | 0.00 | 0.00 | 0.00 | 0.00 | 2.41 |
| D/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV/Sales | 0.00 | 0.00 | 0.00 | 10.82 | 15.70 |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | 29.83 | 41.75 |
| Interest Coverage | 97.81 | 129.57 | 198.40 | 133.07 | 381.89 |
| ROCE | 26.28% | 18.91% | 21.78% | 23.58% | 20.37% |
| ROE | 19.80% | 13.32% | 15.79% | 21.20% | 16.89% |
Key Highlights: FY21:
- The Company registered a stable growth in markets of USA, Europe, Canada and Australia during the quarter and for the full year ended March 31, 2021 on back of new launches and volume growth in existing portfolio supported by the increased capacity.
- The Company has launched new products like Micafungin and Bivalirudin in RTU format as well as Olapatadine Ophthalmic product in branded market.
- The Company has reported a strong growth in Rest of the world market driven by new partnerships and increased penetration geographically. The Company has entered new markets like Singapore, Israel, Saudi Arabia, and CIS Countries
- In Domestic markets, the Company hasramped up Remdesivir supply and maintained sufficient supply of Enoxaparin to support the requirement of COVID patients.
- During the financial year ended March 31, 2021, the Company has filed 21 ANDAs, 5 DMFs and received 32 ANDA approvals
- As at March 31, 2021, the Company has filed total 284 ANDAs, out of which 234 were approved and 50 are pending approval.
INVESTMENT RATIONALE
Capex Plan
Total Capex incurred during FY 2021 was Rs. 228.8 Cr. compared to Rs. 194.7 Cr. for the previous financial year. The Company is expanding its sterile injectable facility located in Hyderabad. It is also enhancing its production capacity for APIs in Vizag and adding capacity in its oncology facility to take care of the planned launches in forthcoming years. Additionally, the Company will be investing in the drug substance and biologics facility for creating robust infrastructure in vaccine and bio-similar space.
Strong Growth in Core Markets
The Company’s core markets consist of the US, Europe, Australia and Canada. Collectively, these countries/core markets constitute around 68% of the company’s overall FY2021 revenues. Gland’s revenues from core markets grew by 22% for FY2021 with US sales growing by 21% to Rs 2126 Cr. and constituted around 90% of the core market revenues. Growth could be largely attributable to the volume pick up in existing products coupled with new product launches such as – Micafungin, Bivalirudin and Ziprasidone offering a significant addressable market opportunity.
The Company has a strong product pipeline in the US with a total of 284 ANDA fillings done as of FY2021 and of these, Gland has received an approval for 234 ANDAs while 50 are awaiting approval. In FY2021, Gland received approvals for 32 ANDAs and launched around 28. Going ahead, the Company expects to launch around 35 molecules in FY2022 and looks to file around 20-22 ANDAs including the complex molecules.
Sputnik V Vaccine Arrangement
The Company has entered in to an arrangement with the Russian RDIF to manufacture 252 million doses of the latter’s COVID-19 vaccine – Sputnik V. Gland Pharma has entered in to a technology transfer arrangement and has consequently acquired assets of a biopharma company entailing an investment of Rs 90 Cr. Subsequently, the Company has also lined up an investment plan to tune of Rs 270 Cr. towards setting up the drug substance manufacturing facility and a fill n finish plant for the said vaccine contract. The contract is for the manufacturing 252 million doses of Sputnik V vaccine and RDIF is bound by the terms of the agreement for the offtake of the vaccine.
Factoring a price of $ 1.5 per dose of the vaccine and assuming a volume of 252 million doses, the total opportunity from vaccines translates to around Rs 2800 Cr. spread over the next two years, starting FY2022-end.
Unique Diversified B2B Led Model
The Company follows a unique diversified B2B led model across markets globally. In the domestic markets, Gland follows a B2C model. Gland Pharma has an extensive portfolio of complex products, awaiting to be commercialized across markets. The Company is looking to build its presence on the Europe market through the inorganic route and is also open for an acquisition in the complex API space.
The Company is a niche player, focused on injectables. It has proven track record of growth and profitability along with a consistent regulatory compliance history. It has never received a negative USFDA report. The Company has extensive and vertically integrated Injectables manufacturing capabilities. US markets constitute a share of 67% of sales and, hence, a strong compliance track record augurs well. Improved demand traction and incremental capacities coming on-stream, provide ample visibility on growth ahead.
The recent arrangement of manufacture 252 million doses of Sputnik vaccine would just take the company closer to its long-term strategy to enter the lucrative Biosimilar space. Being an established player in the injectables, Gland is set to benefit from the rising preference for injectables
About Author
